Tod Nestor
Analyst · H.C. Wainwright
Thank you, James. First, I'd like to summarize our 2020 full year results. Net sales for the full year 2020 were $16.8 million, up 32.5% compared with $12.7 million in 2019. The year-over-year increase in net sales was primarily driven by an increase in military sales, which is partially offset by a decline in commercial sales as a result of fluctuations in the timing, pace and size of commercial projects, including, principally, the impact from the COVID-19 pandemic, the FOS or delay in lighting retrofit projects across the board in the commercial sectors, as James mentioned earlier. From a segment mix perspective, military sales were $11.4 million, representing 67.9% of total net sales compared to $4.8 million or 38% of total net sales for 2019. Sales to commercial customers were $5.4 million in 2020, representing 32.1% of total net sales for the year, down from $7.9 million or 62% of total net sales in 2019. The year-over-year decrease in commercial sales was mainly due to overall softness in the commercial market that began with the onset of the COVID-19 pandemic. Gross profit for 2020 was $5.2 million compared with $2 million in 2019, an increase of 162.7% year-over-year that was driven by an increase in military sales dollars and mix, as well as improved efficiency in our plant operations. As a percentage of revenue, gross profit margin was 30.8% in 2020, compared to 15.5% in 2019, a nearly twofold increase. This increase was primarily due to a more favorable product mix and the margin impact from increased military sales which more than offset unexpected additional manufacturing costs due to supply chain challenges relating primarily to military and maritime products. Adjusted gross margin, a non-GAAP measure, was 27.1% for full year 2020 compared to 15.9% in the prior year. Operating expenses in 2020 were $9.3 million or 54.9% of sales compared to $8.9 million or 70.3% of sales in 2019 or a 3.7% increase year-over-year, however, which was leveraged by the 32.5% increase in net sales. The increase in spending was driven by higher product development and testing costs related to the development and launch of our EnFocus products and development of our UVCD products and higher SG&A due to increased salaries and benefits for headcount to support our growth initiatives. Loss from operations for 2020 was $4.1 million compared to a loss from operations of $7 million in 2019, a year-over-year improvement of $3.1 million. Our core operating business continues to improve, as we remain focused on leveraging our operations as we grow and through continued diligent cost management through strategic sourcing efforts and belt tightening. Below the operating line, interest expense, including interest on borrowings and noncash amortization of facility fees was $481,000 in 2020 compared with $317,000 in 2019. This increase was the result of an increase in borrowings under our new short-term credit facilities that provided increased borrowing capacity. Also, below the operating line, we had nonrecurring expenses of $276,000 for the extinguishment of former revolving line of credit, as well as our early payoff of the bridge financing and a loss of $1.1 million for the market value change in our warrant liabilities. Importantly, in December, certain of the terms of our outstanding warrants were modified, such as the warrants now qualify for equity accounting treatment going forward. At the time of the modification, the liability related to the remaining warrants was fair valued with the offsetting adjustment recorded in income. The warrant liability was then reclassified into equity and the warrants are no longer subject to remeasurement at each balance sheet date. Consequently, this reclassification has added the benefit of eliminating the volatility risk to our net income that can result from periodic valuation of warrants that are classified as a liability. Net loss for 2020, inclusive of the nonoperating expenses and impact of the warrant valuation was $6 million or $1.83 loss per basic and diluted share based on 3.2 million fully diluted shares compared with a loss of $7.4 million or $2.99 loss per basic and diluted share in 2019, which is based on 2.5 million fully diluted shares. Adjusted EBITDA, a non-GAAP measure, which excludes depreciation and amortization, interest expense, stock based and other incentive comp was a loss of $3.5 million for 2020 compared with a loss of $5.9 million in 2019. Now I would like to turn to a brief review of fourth quarter results. Net sales for the fourth quarter of 2020 were $3.7 million, up 6.1% compared with $3.5 million in the fourth quarter of 2019. The year-over-year increase in net sales was primarily driven by an increase in military sales, which was partially offset by a decline in commercial sales as a result of fluctuations in the timing, pace and size of commercial projects, including the impacts of the COVID-19 pandemic. When compared to $6 million in the third quarter of 2020, net sales were down 37.2% on a sequential basis, due in large part to decreased sales in our military business, resulting primarily from the timing of one particular military order that shifted a significant portion of sales from the second quarter of 2020 to the third quarter, resulting in an excess concentration of military sales in the third quarter, as we had previously mentioned. Sales to our top 10 customers for the total company for the fourth quarter of 2020 increased 6.1% and sales to our top 20 customers increased 4.8% compared to the fourth quarter of last year, reflecting further penetration into the top-tier of our existing customer base. From a mix perspective, military sales were $2.6 million for the fourth quarter of 2020, representing 69.2% of net sales compared to $1.5 million or 42.5% of total net sales for the fourth quarter of 2019. The year-over-year increase in military sales is primarily due to increased sales to one of our top 10 customers compared to last year with one particular military customer representing most of the increase. Also, fourth quarter net sales to our top 10 military customers increased 66.9% and net sales to our top 20 military customers increased 67.3% compared to the fourth quarter of 2019. Sales to commercial customers were $1.1 million in the fourth quarter of 2020, representing 30.8% of total net sales for the quarter, down from $2 million or 57.5% of total net sales in the fourth quarter of 2019. The year-over-year decrease in commercial sales was mainly due to overall softness in the commercial market that began at the onset of the COVID-19 pandemic. Sequentially, net sales to commercial customers decreased 20.7%, down from $1.5 million in the third quarter of 2020. This decrease was primarily driven by the pandemic. Fourth quarter 2020 net sales to our top 10 commercial customers decreased 53.6% year over year. And fourth quarter net sales to our top 20 commercial customers decreased 51.8%. As a percentage of revenue, gross profit was 38.3% in the fourth quarter of 2020 compared to 27.1% in the fourth quarter of 2019, a year-over-year increase of 1,120 basis points. This increase was primarily due to a more favorable product mix and the margin impact from increased military sales, as well as more favorable reserve movements in 2020. On a sequential basis, gross profit margin increased 1,520 basis points from 23.1% in the third quarter of 2020. Adjusted gross profit margins for excess and obsolete, in-transit and net realizable value inventory reserve resulted in the non-GAAP adjusted gross margins of 27.7% for the fourth quarter of 2020, more in line with recent historical trends compared to 28.5% in the fourth quarter of 2019 and 24.6% in the third quarter of 2020. Operating expenses in the fourth quarter of 2020 were $2.3 million or 61.4% of sales compared to $2.1 million or 60.2% of sales in the fourth quarter of 2019, an increase of $173,000 or 8.1% year-over-year. The increase was largely driven by higher product development costs related to the development of our UVCD products. Loss from operations for the fourth quarter of 2020 was $866,000 compared to a loss from operations of $1.2 million in the fourth quarter of 2019, a year-over-year improvement of approximately $300,000. Sequentially, this compares to a loss from operations of $1 million in the third quarter of 2020, an improvement of $146,000. Below the operating line, interest expense was $137,000 in the fourth quarter of 2020 compared with $181,000 in the fourth quarter of 2019. This decrease was the result of a lower blended interest rate on borrowings despite the higher debt balance. Also, below the operating line in the fourth quarter, we had nonrecurring expenses of $117,000 for the extinguishment of debt and $1.2 million gain related to the valuation of the warrants. As I mentioned earlier, these warrants were reclassified into equity and will be subject to -- will not be subject to remeasurement in subsequent periods. Net income in the fourth quarter of 2020 was a positive $65,000 or $0.01 per basic and diluted share based on 4.3 million of fully diluted shares compared with a loss of $1.3 million or $0.53 on a loss per basic and diluted share basis based on 3.3 million of fully diluted shares in the fourth quarter of 2019. Now I'd like to turn to the balance sheet. As of December 31, 2020, we had cash of $1.8 million compared to $350,000 at the end of 2019. The increase in cash was primarily due to the insurance of new capital through the sale of equity in the first quarter, as well as increased borrowings. Total debt as of December 31, 2020, was $3.1 million, which was comprised of $2.3 million in short-term credit line borrowings and borrowings of $795,000 under the Paycheck Protection Program as part of the Coronavirus Aid, Relief and Economic Security, or CARES, Act. We applied for loan forgiveness in October 2020 and it was subsequently granted in February of 2021, which included the entire principal balance and interest. In accordance with GAAP, the forgiveness income will be recorded as other income in the consolidated statements of operations during 2021. We estimate there will be a positive impact to other income of approximately $800,000 in the first quarter. For enterprise value purposes, our net debt was $1.3 million at the end of 2020, which compares to net debt of $3.1 million at the end of 2019, a $1.8 million reduction year-over-year. As of December 31, 2020, we had total availability of $3.5 million, which was comprised of $1.8 million of cash and $1.7 million of excess borrowing availability under our credit facilities, primarily as a result of additional capacity gain through our new credit facility, the PPP loan and the equity offering. This compares to $1.9 million in total availability at the end of fiscal 2019. Now I would like to discuss the full year cash flow results. Cash used in operations was $2.5 million for 2020. The net loss was $6 million, inclusive of noncash items, such as depreciation, stock-based compensation and $1.1 million loss from the change in fair value of the warrants. We generated cash from working capital of $2.3 million in 2020 compared to [indiscernible] of $412,000 of cash in 2019. $1.1 million was generated from inventories and $1.1 million was generated from accounts payable, both driven by timing of inventory and a $400,000 was generated from accounts receivable, driven by timing of collections. Cash used in investing was $223,000 or approximately 1% of net sales. Historically, our capital spending requirements were not significant. Net cash provided by the financing activities was $4.1 million, driven primarily by the equity we issued in January, as well as the PPP loan. As I mentioned during prior earnings calls, for the time being, we would like to provide brief updates about the impact of the COVID-19 pandemic on our business. As in the past, we continue to operate under our customized COVID-19 contingency plan at the company with employees that can alternatively work from our plant and office or from their homes. James and I have already discussed the historical impact of the COVID-19 pandemic on our commercial business. While there are small signs that the commercial business might be starting to rebound a bit, it is still too early to become overly optimistic of a rapid or immediate recovery. During the fourth quarter of 2020 and through today, the impact of the pandemic has significantly impacted many businesses, including ours, and resulted in supply chain impacts, such as increased wait times for products to arrive as well as increased inbound and outbound freight and shipping costs, some of which can be passed along to customers, plus continued staffing challenges and other operational hurdles we have had to overcome. Fortunately, we continue to not see a significant impact of the COVID-19 pandemic on our military and maritime business unit. However, thankfully, the development and launch of the UVCD portfolio of products is a good countervailing influence to the pandemic's impact on our commercial business, is consistent with our human health centric approach to lighting, fits very strategically into our long-term goals, and we believe is a long-term business model that will address a lasting focus on sanitation in the workplace, consumer space and social gathering spaces following the COVID-19 pandemic event. The UVCD portfolio addresses all pathogens, including the coronavirus and influenza. Hence, we are entering this segment strategically and with a long-term view. With that, we would like to open up the call to questions.